Affordable Access

Combined radiotherapy and radioimmotherapy of human colon carcinoma grafted in nude mice.

Publication Date
  • Radiotherapy
  • Monoclonal Antibody.
  • Radioimmunotherapy
  • Tumor Regrowth Delay
  • Tumor (Volume) Doubling Time
  • Carcinoembryonic Antigen
  • Human Health Sciences :: Hematology [D11]
  • Sciences De La Santé Humaine :: Hématologie [D11]
  • Human Health Sciences :: Oncology [D15]
  • Sciences De La Santé Humaine :: Oncologie [D15]
  • Medicine


The effect of combined radioimmunotherapy (RIT) and fractionated external beam radiotherapy (RT) was assessed in two human colon cancer xenografts, Col 12 and LS174T in nude mice. These tumors were selected for being resistant to RIT alone, as is usually the case in the clinical situation. Tumor-bearing mice were treated with a combination of five X-ray fractions over 5 days followed by RIT with two doses of 1.5 mCi 131I-labeled anticarcinoembryonic antigen monoclonal antibody F(ab')2. In Col 12 and LS174T, RIT alone achieved a regrowth delay similar to that of fractionated RT with total doses of 28 and 26 Gy, respectively. In both tumor types, an additive therapeutic effect, measured as increased regrowth delay or local control, was observed when combining RT of different dose levels with RIT. Normal tissue responses were assessed by monitoring acute peak skin reactions and blood cell count. Bone marrow depression for the combination treatment was similar to that of RIT alone; relative to skin, at equitoxic levels, no mice bearing Col 12 tumors were locally controlled with a 32 Gy RT dose alone, while this RT combined with RIT gave a local control of 100%. These studies show a therapeutic benefit when external beam RT is combined with RIT.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times